New line of attack against advanced prostate cancer in a study led by a Catalan scientist
The Catalan Media Corporation, La Razón and Aldia.cat have highlighted a study conducted by Xavier Salvatella, ICREA researcher at IRB Barcelona, and published in the journal Structure early in December. In this work, he proposes various ways to tackle prostate cancer and focuses on the androgen receptor protein, which tumour cells need to survive and proliferate.
Link to CCMA
Link to La Razón
Link to Aldia.cat
Related content
News
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.
2020 got off to a flying start for Jessica Vitos with the publication of a paper in PNAS addressing how cancer cells exploit the p38 protein to further their growth and division. Jessica, who did her PhD under the supervision of Ángel Nebreda, defended her thesis back in January 2018 and a year later moved away from the bench to join Ysios, a venture capital company.
Published in the journal Nature Cancer, the study analyses how genetic alterations in tumour cells prevent the correct degradation of the proteins involved in tumour development and growth, thereby leading to abnormal cell behaviour.
A machine-learning model has allowed the scientists to obtain the most extensive annotation of the ubiquitin-mediated protein degradation system.
The analysis proposes a potential new clinical approach for cancer through the inhibition of oncoproteins with impaired degradation systems.
